Leaving the study early · Adults with PTSD for at least 3 months
It is very uncertain whether other therapies changes leaving the study early due to any reason compared with waitlist/Usual Care (very low certainty).
1 finding from 1 review
Leaving the study early · Adults with PTSD for at least 3 months
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · Adults with PTSD for at least 3 months
1 finding from 1 review
Leaving the study early · Adults with PTSD for at least 3 months
It is very uncertain whether trauma‐focused CBT/Exposure therapy changes leaving the study early for any reason compared with non‐TFCBT (very low certainty).
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · Adults with PTSD for at least 3 months
1 finding from 1 review
Leaving the study early · Adults with PTSD for at least 3 months
It is very uncertain whether trauma‐focused CBT/Exposure therapy changes leaving the study early for any reason compared with other therapies (very low certainty).
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · Adults with PTSD for at least 3 months
1 finding from 1 review
Leaving the study early · Adults with PTSD for at least 3 months
It is very uncertain whether EMDR changes leaving study early for any reason compared with waitlist/Usual Care (very low certainty).
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · Adults with PTSD for at least 3 months
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with TCAs (moderate certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ side effects ‐ compared with ABT‐200 (low certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
It is very uncertain whether fluoxetine changes failure to complete ‐ side effects ‐ compared with phenelzine (very low certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with pramipexole (low certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ total ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ side effects ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with reboxetine (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine probably leads to lower failure to complete ‐ total ‐ compared with reboxetine (moderate certainty).
1 finding from 1 review